Neogap Therapeutics selected to join EIC Soft-landing Programme, supporting international growth
Ella Day | May 15, 2025 | News story | Medical Communications, Sales and Marketing |Â Â Corporate, European Innovation Council (EIC), Immunology, Neogap Therapeutics, US pharma market, biotech, immunotherapyÂ
Swedish biotech company, Neogap Therapeutics, has been selected to participate in the EIC Soft-landing Programme for Healthcare and Life Sciences in Boston, US. Alongside other major biotech companies, it will showcase its technology to investors and potential partners, strengthening its presence in the US pharma market.
Organised by the European Innovation Council, the EIC Soft-landing Programme provides support and opportunities to connect with investors, academic institutions and life sciences stakeholders in Boston, a global hub for oncology and biotechnology. The invited attendees participate in a preparatory phase during the spring, before presenting to investors and joining networking sessions between 9 and 13 June.
Neogap’s development of personalised immunotherapy using a combination of artificial intelligence (AI), bioinformatics and cell biology closely aligns with the programme’s focus on deep tech companies.
Its leading asset, pTTL, is a personalised cell-based immunotherapy designed to enhance patients’ T-cells to fight solid tumours. It is based on the company’s technologies PIOR and EpiTCer which use sequencing data and machine learning algorithms to select tumour-specific mutations. Currently, the therapy is being assessed in phase 1 and 2 studies of advanced colorectal cancer.
Neogap’s participation supports its international growth. “Being selected for the EIC Soft-landing Programme is a strong validation of the relevance of our technology in a global innovation context. This programme offers us a concrete opportunity to strengthen our presence in the US market and build new relationships,” said Samuel Svensson, CEO of Neogap Therapeutics.
Ella Day
15/5/25
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
